International Biotechnology Return On Equity vs. Total Debt
| IBT Stock | 684.00 10.00 1.48% |
For International Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of International Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well International Biotechnology Trust utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between International Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of International Biotechnology Trust over time as well as its relative position and ranking within its peers.
International |
International Biotechnology Total Debt vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining International Biotechnology's current stock value. Our valuation model uses many indicators to compare International Biotechnology value to that of its competitors to determine the firm's financial worth. International Biotechnology Trust is rated below average in return on equity category among its peers. It is rated below average in total debt category among its peers making up about 162,238,806 of Total Debt per Return On Equity. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the International Biotechnology's earnings, one of the primary drivers of an investment's value.International Total Debt vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
International Biotechnology |
| = | 0.14 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
International Biotechnology |
| = | 22.83 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
International Total Debt vs Competition
International Biotechnology Trust is rated below average in total debt category among its peers. Total debt of Financials industry is currently estimated at about 8.47 Billion. International Biotechnology adds roughly 22.83 Million in total debt claiming only tiny portion of equities under Financials industry.
International Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in International Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, International Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of International Biotechnology's change in net profit over the period of time. It can combine multiple indicators of International Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 296.1 M | 310.9 M | |
| Operating Income | 37.9 M | 19.7 M | |
| Income Before Tax | 39 M | 19.7 M | |
| Net Income | 38.9 M | 20.4 M | |
| Net Loss | -20.2 M | -19.2 M | |
| Total Other Income Expense Net | 1.1 M | 1.2 M | |
| Income Tax Expense | 135 K | 97.5 K | |
| Net Income From Continuing Ops | 38.9 M | 19.5 M | |
| Net Interest Income | -2 M | -1.9 M | |
| Interest Income | 218 K | 228.9 K | |
| Change To Netincome | 3.9 M | 3.5 M |
International Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on International Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of International Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the International Biotechnology's important profitability drivers and their relationship over time.
Use International Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if International Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in International Biotechnology will appreciate offsetting losses from the drop in the long position's value.International Biotechnology Pair Trading
International Biotechnology Trust Pair Trading Analysis
The ability to find closely correlated positions to International Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace International Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back International Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling International Biotechnology Trust to buy it.
The correlation of International Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as International Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if International Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for International Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your International Biotechnology position
In addition to having International Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Municipals ETFs Thematic Idea Now
Broad Municipals ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Municipals ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Municipals ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in International Stock
To fully project International Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of International Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include International Biotechnology's income statement, its balance sheet, and the statement of cash flows.